[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Northwestern University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":610},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,180,0,25,[9,41,63,85,108,129,149,173,212,235,253,276,300,327,350,377,393,412,438,465,489,517,536,561,588],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100054290",false,"NCT06391073","Reach Out 2: Emergency Department-Initiated Hypertension Mobile Health Intervention Connecting Multiple Health Systems","Reach Out 2: Randomized Clinical Trial of Emergency Department-Initiated Hypertension Mobile Health Intervention Connecting Multiple Health Systems","While in the ED, the patient must meet all of the following:\n\n* Adult (≥18 y\u002Fo)\n* At least one BP with Systolic BP ≥160 or a Diastolic BP ≥100 (criteria 1)\n* If the patient has repeated measurements after achieving Criteria 1, at least one of the repeat BP remains systolic BP ≥140 or a diastolic BP ≥90\n* Must have cell phones with text-messaging capability\n* Likely to be discharged from the ED\n\nExclusion Criteria for Main Trial Participants:\n\n* Critical illness\n* Unable to read English (\\\u003C1% at study site)\n* Incarcerated\n* Pregnant\n* Pre-existing condition making 6-month follow-up unlikely","ALL","18 Years","99 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","Emergency department visits provide an opportunity to identify people with undiagnosed, untreated, or uncontrolled high blood pressure. In Reach Out, we will test whether a mobile health intervention yields a greater reduction in blood pressure than usual care among individuals identified with high blood pressure during a safety-net emergency department visit. Subsequently, we will estimate the reduction in heart attack, stroke, and dementia if Reach Out were implemented across all U.S. safety-net emergency departments.",[27],"Hypertension","RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2024-07-22",{"date":36,"type":21},"2028-11-30",{"name":38,"class":39},"Northwestern University","OTHER",1,{"id":42,"slug":4,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":17,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100610175","NCT07224165","Developing a Digital Intervention for Adolescent Nonsuicidal Self-injury","Inclusion Criteria:\n\n* Current NSSI (NSSI on 2 or more days in the last month\n* English language skills sufficient to engage in the consent and intervention procedures\n* Age 14-18\n* Access to smartphone\n\nExclusion Criteria:\n\n* Severe mental health diagnoses for which this intervention would be inappropriate (psychotic disorders, active manic episodes)\n* Severe suicide risk, including suicidal ideation with a plan and intent to act\n* Current engagement in psychotherapy","14 Years",{"count":48,"type":21},80,[24],"This is a feasibility trial of a digital mental health intervention aimed at adolescents (ages 14-18) with nonsuicidal self-injury and who are not currently engaged in mental health treatment. The study has two arms: a self-guided DMHI and an active control which will involve the delivery of non-interactive psychoeducational content via the same app interface. The primary goals of this project are to evaluate the feasibility of the intervention and trial procedures in preparation for a fully-powered randomized-controlled trial.",[52,53,54],"Nonsuicidal Self-injury","Depression","Anxiety","2026-07-01",{"date":57,"type":32},"2026-07-02",{"date":59,"type":32},"2026-06-04",{"date":61,"type":21},"2027-07-31",{"name":38,"class":39},{"id":64,"slug":4,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":69,"minAge":4,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100578638","NCT06813898","An Investigational Scan (rhPSMA-7.3 PET\u002FCT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial","ENLIGHTEN: Detection by POSLUMA Following Negative Other PET-PSMA Imaging","Inclusion Criteria:\n\n* Men with a history of prostate adenocarcinoma treated with local therapy (including radical prostatectomy or radical prostatectomy and secondary therapy \\[i.e. salvage radiation\\])\n* Men must have biochemical recurrence (defined as PSA \\>= 0.1ng\u002Fml) after therapy\n* PSA \\\u003C 0.5ng\u002Fml (within 90 days of enrollment)\n* Men must have had negative or equivocal PET PSMA based imaging with 90 days of enrollment with an Food and Drug Administration (FDA) approved non-POSLUMA tracer\n* Non-castrate testosterone (testosterone \\[T\\] \\> 50ng\u002FdL) within 90 days of study entry\n* Institutional Review Board (IRB)-\u002FIndependent Ethics Committee (IEC)-approved written informed consent and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures\n* Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on the study\n* Concurrent diseases and malignancies are permitted\n\nExclusion Criteria:\n\n* Most recent PSA not between 0.1ng\u002Fml and 0.5ng\u002Fml\n* Men with non-metastatic castrate resistant prostate cancer (defined as rising PSA and T \\\u003C 50ng\u002Fdl)\n* Patients receiving 5-alpha reductase inhibitors, androgen deprivation therapy and androgen receptor antagonists within 3 months of enrollment (men may start these therapies at physician discretion immediately following POSLUMA PET PSMA scan)","MALE",{"count":71,"type":21},27,[73],"EARLY_PHASE1","This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography \\[PET\\]\u002Fcomputed tomography \\[CT\\]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following prior treatment (biochemical recurrence) but who were prostate specific membrane antigen negative on their most recent PET scan. Contrast agents like rhPSMA-7.3 (also called POSLUMA) circulate in the blood until they find their intended target. Once they are taken up by the target tumor cells, they can be visualized using PET\u002FCT cameras. A PET scan is a procedure in which a small amount of radioactive tracer (in this case rhPSMA-7.3) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the tracer is taken up. Because tumor cells often take up more tracer than normal cells, the pictures can be used to find tumor cells in the body. A CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional views of tissues and organs. Combining a PET scan with a CT scan can help make the image easier to interpret. PET\u002FCT scans are hybrid scanners that combine both modalities into a single scan during the same examination. The researchers want to determine whether the rhPSMA7.3 PET\u002FCT scan is useful for detecting biochemically recurrent prostate cancer in patients who were negative on prior non-POSLUMA PET imaging.",[76,77],"Biochemically Recurrent Prostate Carcinoma","Prostate Adenocarcinoma","2026-06-30",{"date":57,"type":32},{"date":81,"type":32},"2025-04-11",{"date":83,"type":21},"2032-02-01",{"name":38,"class":39},{"id":86,"slug":4,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100520894","NCT06062498","Elacestrant vs Elacestrant Plus a CDK4\u002F6 Inhibitor in Patients With ERpositive\u002FHER2-negative Advanced or Metastatic Breast Cancer","Randomized Phase II Study of Elacestrant vs Elacestrant Plus a CDK4\u002F6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) in Patients With ER+\u002FHER2- Advanced or Metastatic Breast Cancer With Prior Exposure to a CKD4\u002F6 Inhibitor","Inclusion Criteria All Arms:\n\n* Patients must have histologically or cytologically confirmed ER-positive and HER2- negative breast cancer as per the American Society of Clinical Oncology (ASCO)\u002FCollege of American Pathologists (CAP) guidelines (Allison et al, 2020, Wolff et al, 2018).\n\nNote: In the context of this trial, ER status will be considered positive if \\>10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry. Note: Fresh biopsy is not a requirement.\n\n* Patients must have a confirmed ESR1 mutation. Note: This information will be drawn from patients' treatment charts. Mutational analysis will be done as standard of care; there is no research-related mutational testing for this study. ctDNA may be used for mutational testing.\n* Patients must have at least one measurable lesion (as per RECIST v1.1) lesion anywhere in the body or a mainly lytic metastatic bone lesion. Note: Lytic bone lesions with identifiable soft tissue components that can be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered as measurable lesions if the soft tissue component meets the definition of measurability per RECIST v1.1.\n* Patients must have received at least 2 prior endocrine therapies, including a CDK4\u002F6 inhibitor in the metastatic disease setting.\n* Patients must be age ≥ 18 years. Patients of childbearing potential (POCBP) may be premenopausal, postmenopausal, or perimenopausal.\n* Potential POCBP who may be menopausal and are \\\u003C 55 years of age must have a serum follicle-stimulating hormone (FSH) level \\> 40 mIU\u002FmL to confirm menopause.\n* Patients must exhibit an ECOG performance status of 0 or 1.\n* Patients must have adequate organ and bone marrow function as defined below:\n\nLeukocytes (WBC) ≥ 3,000\u002FmcL Absolute neutrophil count (ANC) ≥ 1,500\u002FmcL Hemoglobin (Hgb) ≥ 80-100 g\u002FdL Platelets (PLT) ≥ 50,000\u002FmcL Total serum bilirubin \\\u003C 1.5 x Institutional upper limit of normal (ULN) AST (SGOT) ≤ 3 x institutional ULN (no liver metastases)\n\n* 5 x institutional ULN (liver metastases present) ALT (SGPT) ≤ 3 x institutional ULN\n* 5 x institutional ULN (liver metastases present) Cockcroft-Gault based creatinine clearance\n\n  * 50 mL\u002Fmin\n\nNote:\n\n* Creatinine clearance (DMAB)\n\n  = (\\[140-age in years\\] × weight in kg)\u002F (\\[serum creatinine in mg\u002FdL\\] × 72)\n* Creatinine clearance (DFAB) = (0.85 × \\[140-age in years\\] × weight in kg)\u002F (\\[serum creatinine in mg\u002FdL\\] × 72) Note: Growth factor\u002Ftransfusion support to attain these levels is not permitted.\n\n  * For patients with a known history of human immunodeficiency virus (HIV), infected patients on effective anti-retroviral therapy must have a viral load undetectable for 6 months prior to registration.\n  * For patients with a known history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n  * Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n  * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are eligible.\n  * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better. Elacestrant is a known teratogen. For this reason, patients of child-bearing potential (POCBP) and their partners with sperm-producing reproductive capacity must agree to use adequate contraception (see Appendix B) from time of informed consent, for the duration of study participation, and for 7 days following completion of elacestrant therapy.\n\nShould a POCBP become pregnant or suspect they are pregnant while they or their partner are participating in this study, they should inform their treating physician immediately. Patients with sperm-producing reproductive capacity (PWSPRC) treated or enrolled on this protocol must also agree to use adequate contraception with partners of childbearing potential from time of informed consent, for the duration of study participation, and 7 days after completion of administration. Note: A POCBP is any patient (regardless of gender, sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) with an egg-producing reproductive tract who meets the following criteria:\n\n* Has not undergone a hysterectomy or bilateral oophorectomy\n* Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months) Note: POCBP who are on combination therapy with any study CKD4\u002F6 inhibitor (palbociclib, abemaciclib, or ribociclib) must agree to use adequate contraception from time of informed consent, for the duration of study participation, and for 21 days following completion of CKD4\u002F6 inhibitor therapy. POCBP must have a negative pregnancy test prior to registration on study. If initial urine pregnancy test is positive or cannot be confirmed negative, serum pregnancy test will be required. -Patients must have the ability to understand and the willingness to sign a written informed consent document.\n\nInclusion Criteria - Combination Therapy Arm 2 with Palbociclib, Abemaciclib, or Ribociclib\n\n-Patients who have been treated with one or two prior hormonal therapies in the metastatic setting if at least one hormonal therapy was in combination with a CDK4\u002F6 inhibitor.\n\nNotes:\n\n* Patients who are already on or have already been exposed to one or two of the study CDK4\u002F6 inhibitors at registration will be assigned a different study CDK4\u002F6 inhibitor (e.g., if a patient has already been exposed to abemaciclib, they will be given ribociclib or palbociclib; similarly, if a patient has already been exposed to palbociclib and abemaciclib, they will be given ribociclib.)\n* One-to-one randomization will be done by the QA team once patients have been registered.\n\nExclusion Criteria All Arms:\n\n* Patients who have received prior elacestrant.\n* Patients who have had chemotherapy or radiotherapy ≤ 28 days (6 weeks for nitrosureas or mitomycin C) prior to registration.\n* Patients who have taken steroid therapy or any other immunosuppressive therapy within 7 days of first dose prior to trial treatment.\n* Patients with brain metastases. Note: Patients with stable brain or subdural metastases are allowed if the patient has completed local therapy and was on a stable or decreasing dose of corticosteroids at baseline for brain management for at least 4 weeks before starting treatment in this study. The dose must be \\\u003C2.0 mg\u002Fday of dexamethasone or equivalent. Any signs (e.g., radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment. RANO criteria are used to evaluate brain metastases\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 3) with the exception of alopecia.\n* Patients who are receiving any other investigational agents. For patients who were previously on palbociclib, abemaciclib, or ribociclib, the washout period between stopping that CDK4\u002F6 inhibitor and starting a different one is 14 days.\n* Patients with advanced, symptomatic visceral spread who are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis, or liver involvement \\>50%.\n* Patients with documented pneumonitis\u002Finterstitial lung disease prior to registration.\n* Patients who have received major surgery within 28 days before starting trial therapy.\n* Patients who are taking strong or moderate CYP3A4 inducers or strong or moderate CYP3A4 inhibitors. See Section 4.4 for additional incompatibilities.\n* Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to elacestrant. Note: Refer to exclusion criteria below for eligibility criteria related to study CDK4\u002F6 inhibitors.\n* Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following:\n\n  * Hypertension that is not controlled on medication\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints\n* Patients with refractory or chronic nausea, gastrointestinal conditions (including significant gastric or bowel resection or gastric bypass surgery), history of malabsorption syndrome, or any other uncontrolled gastrointestinal condition that impact the absorption of the study drug. Similarly, patients who are unable to take\u002Fretain oral medications.",{"count":92,"type":21},174,[94],"PHASE2","Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied nature of the disease, development of resistance to this therapeutic approach is very common in the metastatic setting.\n\nThe purpose of this study is to see whether the effectiveness of elacestrant can be enhanced by combining it with a targeted agent such as a CDK4\u002F6 inhibitor to treat patients with ER+\u002FHER2- or metastatic breast cancer with prior exposure to a CDK4\u002F6 inhibitor.",[97,98,99,100],"Estrogen-receptor-positive Breast Cancer","HER2\u002FNeu-Negative Breast Cancer","Advanced Breast Cancerv","Metastatic Breast Cancer",{"date":57,"type":32},{"date":103,"type":32},"2023-09-29",{"date":105,"type":21},"2029-07-01",{"name":38,"class":39},3,{"id":109,"slug":4,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":114,"sex":69,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":40},"100504723","NCT05852041","rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance","A Pilot Study of rhPSMA-PET MRI Imaging for the Detection of Clinically Actionable Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance","Inclusion Criteria:\n\n* Healthy men (Eastern Cooperative Oncology Group \\[ECOG\\] 0-1), \\>= 18 years old with at least 10 year life expectancy\n* Histologically proven Gleason Grade Group 1 or 2 adenocarcinoma of the prostate\n* Last prostate cancer containing biopsy performed within 3-15 months (mo.) prior to screening. Biopsy must have been \\>= 10 core biopsy and informed by prior mpMRI\n* Prostate cancer categorized as low risk or favorable risk by National Comprehensive Cancer Network (NCCN) criteria (low risk is defined as T1c-T2a, prostate-specific antigen \\[PSA\\] \\\u003C 10ng\u002Fml, Gleason Grade Group 1 \\[Gleason 3+3=6\\] disease) and favorable intermediate risk as having no more than one of the following intermediate risk features, clinical T2b-T2c disease, PSA 10-20ng\u002Fml, Gleason Grade Group 2 \\[Gleason score 3+4=7\\])\n* Decipher genomic classifier score from prior biopsy \\>= 0.45\n* Institutional Review Board (IRB)-\u002FIndependent Ethics Committee (IEC)-approved written informed consent and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures\n* Concurrent diseases and malignancies are permitted\n* Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on the study\n* Willing to undergo prostate biopsy prior to non-surgical treatment of prostate cancer and within 90 days of PET-MRI imaging\n\nExclusion Criteria:\n\n* Prior radiotherapy, surgery, chemotherapy, or hormonal therapy for prostate cancer\n* NCCN very low risk category (T1c and Gleason Grade Group 1 \\[Gleason score 3+3=6\\], PSA \\\u003C 10 ng\u002FmL, fewer than 3 prostate biopsy cores positive, =\\\u003C 50% cancer in any core, PSA density \\\u003C 0.15 ng\u002FmL\u002Fg)\n* Decipher score \\\u003C 0.45\n* Prior bladder outlet procedure (i.e,. holmium laser enucleation of the prostate \\[HoLEP\\], transurethral resection of the prostate \\[TURP\\], Urolift, Rezum)\n* Prohibited medications: use of 5 alpha reductase inhibitor or androgen deprivation therapy (i.e., leuprolide, relugolix) within 1 month of screening\n* Contra-indication or relative contra-indication to MRI (i.e., pacemaker)\n* History of hip replacement\n* Subject has received investigational therapy within 28 days or 5 half-lives, whichever is longer, prior to screening",true,{"count":116,"type":21},40,[73],"This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer who are candidates for active surveillance. A PET scan is a test that uses a radioactive drug and a computer to create images of how organs and tissues in the body are functioning. The radioactive drug used in this study, rhPSMA-7.3, attaches to the abnormal cells in the body at a different rate than normal cells which allows the scanner to create a detailed picture of how the body is working. An MRI scan uses strong magnets and computers to create detailed images of the soft tissue in your body. A multiparametric (mp)MRI is a type of MRI scan that creates a more detailed picture of the prostate gland. Using rhPSMA-73 with PET-MRI and mpMRI may be more effective in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer.",[77,120,121,122],"Stage I Prostate Cancer AJCC v8","Stage IIA Prostate Cancer AJCC v8","Stage IIB Prostate Cancer AJCC v8",{"date":57,"type":32},{"date":125,"type":32},"2023-06-07",{"date":127,"type":21},"2035-06-07",{"name":38,"class":39},{"id":130,"slug":4,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":40},"100395454","NCT04429308","PDT vs Peels for Treatment of Actinic Keratoses","PDT Versus the Combination of Jessner's Solution and 35% TCA for Treatment of Actinic Keratoses on Upper Extremities: A Randomized Controlled Split-arm Trial","Inclusion Criteria:\n\n1. \\>18 years of age\n2. Interested in receiving treatment for actinic keratoses on the bilateral upper arms\n3. In good general health as assessed by the investigator\n4. Participants must have the ability to understand and the willingness to sign a written informed consent prior to registration on study\n\nExclusion Criteria:\n\n1. Patient pregnant or nursing\n2. Patient with extensive concurrent skin conditions (such as eczema, psoriasis, etc) on upper extremities that would interfere with treatment as determined by the treating physician\n3. Subject unwilling to sign an IRB approved consent form\n4. Participants who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function are not eligible",{"count":136,"type":21},60,[94],"The purpose of this study is to to compare photodynamic therapy (PDT) versus the combination of Jessner's solution and 35% trichloroacetic acid (TCA) chemical peels for the treatment of actinic keratoses on upper extremities.\n\nThis is a randomized clinical trial. Approximately 60 participants with actinic keratoses on both upper arms will be randomized to have one arm receive photodynamic therapy, while the contralateral arm receives Jessner's solution followed immediately by 35% TCA. AKs will be counted before treatment and 2-8 weeks after treatment. This study is a pilot study designed to determine the feasibility of this procedure.\n\nSubjects currently living in the Chicago metropolitan area and meet inclusion\u002Fexclusion criteria will be considered for enrollment.",[140],"Actinic Keratoses","NOT_YET_RECRUITING","2026-06-29",{"date":55,"type":32},{"date":145,"type":21},"2026-08",{"date":147,"type":21},"2027-12",{"name":38,"class":39},{"id":150,"slug":4,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":156,"briefSummary":157,"conditions":158,"keywords":161,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":40},"100357351","NCT03932903","Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia","Using Real Time Mobile Health Approaches to Understand and Promote Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia","AYA Inclusion Criteria:\n\n* Ages 14-29\n* Diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma\n* In the maintenance phase, completed at least one cycle and has at least one month of maintenance therapy remaining.\n* Prescribed 6-mercaptopurine (6MP)\n* English language proficiency\n* For AYA \\<18, must have informed consent from their caregiver.\n\nAYA Exclusion Criteria:\n\n* Cognitive impairments that would limit ability to complete measures, determined by the medical team\n* Absence of inclusion criteria above.\n\nCaregiver Inclusion Criteria:\n\n* Nominated by the AYA as a primary caregiver involved in cancer care (can be a parent, relative, partner, friend)\n* English language proficiency\n\nCaregiver Exclusion Criteria:\n\n\\- Absence of inclusion criteria above.",{"count":136,"type":21},[24],"This is a small-scale micro-randomized clinical trial of a new mobile just-in-time adaptive intervention (JITAI) designed to promote oral chemotherapy adherence in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL). The goals of this study are to determine intervention feasibility and acceptability.",[159,160],"Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma",[162,163,164,165,166],"Adherence","Adolescent","Young Adult","Mobile Health","Oncology",{"date":78,"type":32},{"date":169,"type":32},"2025-07-31",{"date":171,"type":21},"2027-08-31",{"name":38,"class":39},{"id":174,"slug":4,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":69,"minAge":180,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":185,"conditions":186,"keywords":191,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":209,"leadSponsor":211,"locationsCount":40},"100643499","NCT07604272","Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males","Reversing InGuinal Hernia Trial (RIGHT Trial): The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males","RIGHT","Inclusion Criteria:\n\n* Male sex\n* Age ≥ 50 years at time of enrollment\n* Symptomatic unilateral inguinal hernia confirmed on physical examination\n* Hernia visible \u002F confirmed on groin ultrasound\n* Non-recurrent inguinal hernia (primary hernia only)\n* Willing and able to provide written informed consent\n* Able and willing to comply with all protocol-required visits, laboratory assessments, imaging, and follow-up\n* Willing to use contraception and avoid fathering a child during study participation and for 12 months after last dose\n* Willing to be counseled regarding vitamin D and calcium supplementation Bone safety mitigation measure per PIND response.\n\nExclusion Criteria:\n\nHernia Characteristics\n\n* Scrotal hernia (any)\n* Bilateral inguinal hernia\n* Recurrent inguinal hernia (prior repair at same site)\n\nRenal \\& Hepatic\n\n* Clinically significant renal dysfunction judged by investigator to increase study risk\n* Clinically significant hepatic dysfunction at baseline\n\nHematologic\n\n■ Clinically significant baseline hematologic abnormality (including elevated hematocrit or polycythemia)\n\nUrologic \u002F Prostate\n\n* Symptomatic benign prostatic hyperplasia (BPH) requiring active medical or procedural treatment\n* Clinically significant untreated prostate disease\n\nSkeletal \u002F Bone\n\n* Baseline osteoporosis (T-score ≤ -2.5 on DEXA at any site)\n* Recent fragility fracture (within prior 12 months or as judged by investigator)\n* Other clinically significant skeletal vulnerability judged to increase risk from estrogen suppression\n\nImmunosuppression ■ Active immunosuppression (e.g., systemic corticosteroids, biologic agents, post-transplant regimens)\n\nPsychiatric\n\n■ Unstable or uncontrolled psychiatric illness that, in the investigator's judgment, would interfere with safe study participation\n\nReproductive \u002F Fertility ■ Actively pursuing fertility or planning conception during study participation\n\nPrior \u002F Concomitant Therapy\n\n* Current use of androgen replacement therapy, exogenous estrogen, or other endocrine-active agents that would confound study interpretation\n* Prior or current use of aromatase inhibitor or selective estrogen receptor modulator \u002F degrader within 6 months of enrollment\n\nGeneral\n\n■ Any other clinically significant medical condition, laboratory abnormality, or circumstance that, in the investigator's judgment, would place the participant at unacceptable risk or compromise study integrity","50 Years",{"count":182,"type":21},30,[184],"PHASE1","This is a prospective, single-center, three-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias. Participants will be randomized to receive fulvestrant 250 mg intramuscularly, fulvestrant 500 mg intramuscularly, or letrozole 5 mg orally for 6 months. The study will evaluate safety, tolerability, feasibility, hormone changes, hernia size, patient-reported outcomes, bone density, and imaging-based hernia classification.",[187,188,189,190],"Inguinal Hernia Unilateral","Inguinal Hernia Bilateral","Inguinal Hernia Without Obstruction or Gangrene","Inguinal Hernia, Without Mention of Obstruction or Gangrene",[192,193,194,195,196,197,198,199,200,201,202,203,204],"inguinal hernia","hernia","fulvestrant","letrozole","anti-estrogen therapy","aromatase inhibitor","estrogen receptor","ESR1","male inguinal hernia","hormonal therapy","fibrosis","hernia prevention","hernia regression","2026-06-24",{"date":207,"type":32},"2026-06-26",{"date":55,"type":21},{"date":210,"type":21},"2028-06",{"name":38,"class":39},{"id":213,"slug":4,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":40},"100628432","NCT07461558","Watchful Waiting Versus Immediate Repair for Occult Contralateral Inguinal Hernias.","WATCH IT TRIAL WAtchful Waiting Versus immediaTe Repair for Occult Contralateral Hernias Found During MIS Inguinal Hernia Repair Trial.","WATCH IT","Inclusion Criteria:\n\n* Male or female patients ≥18 years old\n* Symptomatic unilateral inguinal hernia\n* Occult contralateral hernia identified intraoperatively\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Prior contralateral inguinal hernia repair\n* Symptomatic, bilateral inguinal hernias confirmed on physical exam\n* Contraindications to general anesthesia or surgery\n* Urgent or emergent presentations\n* Adults unable to consent\n* Pregnant patients",{"count":220,"type":21},380,[24],"This study will compare two ways of managing a small, hidden hernia that can sometimes be found during minimally invasive surgery to repair a hernia on one side of the groin. Occasionally while fixing the known hernia, the surgeon discovers a small hernia on the other side that has not caused any symptoms. Surgeons do not agree on the best way to handle these hernias. Some believe it should be repaired right away during the same operation to prevent it from getting bigger or from causing symptoms later, which could require another surgery. Others believe it is better to leave it alone since it is not causing problems and groin hernia surgery carries risks including long-term pain.\n\nThis study will randomly assign patients, if a hidden hernia is found during surgery, to either having it repaired immediately or to have it monitored over time. Patients will be followed up at 30 days, 1 year and 2 years following surgery. The researchers will compare recovery and quality of life between the two groups. For those in the monitoring group, the study will also track whether the hidden hernia causes symptoms or eventually needs surgery. The goal is to determine whether repairing the hidden hernia right away is as safe and effective as watching and waiting, so doctors and patients can make more informed decisions in the future.",[188,187],[225,226,227,228],"Occult inguinal hernia","Asymptomatic inguinal hernia","Minimally invasive inguinal hernia repair","Transabdominal preperitoneal inguinal hernia repair",{"date":207,"type":32},{"date":231,"type":32},"2026-04-01",{"date":233,"type":21},"2029-04",{"name":38,"class":39},{"id":236,"slug":4,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":252,"locationsCount":40},"100624490","NCT07410312","BRIDGE - Blocking Receptor of IL-1β for Donor Graft Edema Reduction","Inclusion Criteria:\n\n* Age 18 years or older.\n* Planning to undergo transplantation of the lung.\n* Willing and able to read, understand, and be capable of giving informed consent.\n* Use of ex vivo lung perfusion (EVLP) prior to lung transplant.\n\nExclusion Criteria:\n\n* Previous or current use of IL-1R antagonist drug.\n* Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating, such as highly sensitized patients who require additional immunosuppression, multiorgan transplant, and re- transplant.",{"count":241,"type":21},20,[73],"This study will determine if primary graft dysfunction (which causes low blood oxygen levels and fluid or inflammation in the lungs) after lung transplant can be prevented through the use of the study drug (IL-1 receptor antagonist, Anakinra). In this study, lung transplant participants who are randomized to the treatment group will have the study drug injected into the solution that their donor lungs are kept in prior to transplant.",[245],"Lung Transplant Recipient",[247],"lung transplant",{"date":249,"type":32},"2026-06-25",{"date":55,"type":21},{"date":147,"type":21},{"name":38,"class":39},{"id":254,"slug":4,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":265,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":40},"100621050","NCT07365579","Design and Feasibility of an SMS-based Safety Planning Intervention","mHealth for Suicide Prevention: Design, Development, and Feasibility of a Scalable SMS-based Safety Planning Intervention","Inclusion Criteria:\n\n1. Ages 18 to 24 \\*The age to provide consent in Nebraska is 19. Individuals recruited from the state of Nebraska must be 19 or older.\n2. endorsement of past 2-week suicidal ideation\n3. Resident of the United States\n4. Owns a smartphone\n\nExclusion Criteria:\n\n1. Serious mental illness for which intervention would be contraindicated (i.e., active psychosis or mania)\n2. Imminent suicidality (i.e., experiencing active suicidal ideation with a plan and intent to act)\n3. Written English language skills that are insufficient to engage in the consent, design, evaluation, or intervention procedures.","24 Years",{"count":136,"type":21},[24],"This study is testing whether it is feasible to run a larger randomized controlled trial and whether an automated text messaging program is acceptable to young adults who have suicidal thoughts. The program is designed to help participants create and use a safety plan, which is a personalized list of warning signs, coping strategies, supportive people, professional resources, ways to make their environment safer, and reasons for living. After joining and completing an initial survey, participants are randomly assigned by a computer to one of two groups. One group starts right away with the interactive safety planning text program. The other group first receives simple text messages with 24\u002F7 crisis resources and then, after four weeks, also receives the interactive safety planning program. Participants use the text program for about four weeks and complete online surveys at the start and again over a total period of 24 weeks.",[264],"Suicidal Ideation and Behavior",[266,267,268],"Text message","safety plan","suicide prevention","2026-06-23",{"date":249,"type":32},{"date":272,"type":32},"2026-06-02",{"date":274,"type":21},"2027-06-30",{"name":38,"class":39},{"id":277,"slug":4,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":22,"phases":285,"briefSummary":286,"conditions":287,"keywords":290,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":40},"100644062","NCT07669753","Advancing Cancer Control Engaged Research Through Transformative Solutions (ACCERT) Social Determinants of Health (SDoH) Navigation Program","Advancing Cancer Control Engaged Research Through Transformative Solutions in Patient Navigation (ACCERT PN) Center","ACCERT SDoH","Inclusion Criteria:\n\n1. adults 18 years and older;\n2. able to complete verbal survey in English, Spanish, or Mandarin\u002FCantonese Chinese;\n3. reside in Chicago;\n4. able to give informed consent;\n5. agree to a verbal consent document prior to being registered in the study;\n6. has a smart device with access to the internet.\n\nExclusion Criteria:\n\n* Age \\\u003C18\n* Incarceration\n* Adults unable to give informed consent",{"count":284,"type":21},750,[24],"The purpose of this study is to evaluate patient navigation programs designed to reduce barriers to cancer screening and improve healthcare experiences for adults living in Chicago. Participants will be asked to complete two surveys: the first survey shortly after the participants join the study and a second survey after 1 year. Participants will be joining one of three patient navigation programs, assigned at random. The investigators expect the participants to be in this patient navigation program for 12 months, followed by a 1-month window to complete the final survey.",[288,289],"Cancer","Cancer , Healthy",[291,292],"cancer prevention","cancer screening","2026-06-22",{"date":249,"type":32},{"date":296,"type":32},"2026-06-01",{"date":298,"type":21},"2029-08-31",{"name":38,"class":39},{"id":301,"slug":4,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":313,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":320,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":326},"100631243","NCT07498140","Procedural Framing and Epidural Steroid Injection Outcomes","PEACE Study: Psychophysical Enhancement to Augment Conservative and Epidural Steroid Injection Outcomes: A Multi-Center International Randomized Trial","PEACE","Inclusion Criteria:\n\n* Age \\> 18\n* Lumbosacral radicular pain based on history and physical exam (e.g. pain radiating into one or both lower extremities, sensory loss, muscle weakness, positive straight leg raising test etc.)\n* Duration of pain \\>6 weeks\n* NRS leg pain score \\> 4 (or if 3\u002F10, greater or equal to back pain)\n* MRI evidence of spinal pathology consistent with symptoms\n* Candidates for ESI and pharmacotherapy\n\nExclusion Criteria:\n\n* Untreated coagulopathy\n* Previous spine surgery\n* No MRI or non-concordant MRI study\n* Leg pain \\> 15 years duration\n* Epidural steroid injection within past 2 years\n* Signs or symptoms of cauda equina syndrome\n* Previous failed trials with gabapentin and pregabalin and tricyclic antidepressants and duloxetine\n* Allergic reactions to contrast dye prohibiting injection (e.g., tranforaminal ESI), gabapentinoids, tricyclic antidepressants or duloxetine, and contraindications to all of the above medications\n* Referrals from surgery for diagnostic injections for surgical evaluation\n* Serious medical (e.g. congestive heart failure) or psychiatric (untreated depression) condition that might preclude optimal outcome\n* Pregnancy\n* Inability to understand basic English",{"count":308,"type":21},210,[24],"Back pain is the leading cause of disability and military medical boards across the globe. Epidural steroid injections (ESI) are the most commonly performed pain procedure in the world.\n\nThere is strong evidence that the placebo effect for all pain treatments, including ESI, is greater than the intrinsic effect. The placebo effect is highly dependent on a patient's 'expectations', and therefore how the procedure is framed.\n\nThis study aims to compare ESI when the procedure is framed very positively- as is often done in clinical practice vs. more neutrally (which is less commonly done in clinical practice but consistent with evidence). The placebo effect is also stronger for procedures than medications. The evidence on the benefits of ESI is highly dependent on whether it is compiled by interventional doctors who perform the procedure or non-interventional researchers.\n\nIn order to determine how 'framing' a treatment affects pain outcomes, the investigative team will conduct a 3-arm randomized trial comparing positive framing of ESI, neutral framing of ESI, and medications, in patients with lumbosacral radiculopathy.",[312],"Lumbosacral Radiculopathy",[314,315,316,317,318,319],"Back pain","Lumbar radiculopathy","Epidural steroid injection","Placebo effect","Sciatica","Positive framing",{"date":249,"type":32},{"date":322,"type":32},"2026-03-30",{"date":324,"type":21},"2028-06-30",{"name":38,"class":39},4,{"id":328,"slug":4,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":333,"minAge":17,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":22,"phases":337,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":40},"100634473","NCT07540143","The REACH-OUT Trial","A Technology-based, Primary Care Strategy to Optimize Blood Pressure Before Pregnancy: The REACH-OUT Trial","Inclusion Criteria:\n\n* biologically female\n* age 18-44\n* English or Spanish-speaking\n* prescribed an antiHTN\n* have a systolic BP \\>140 or diastolic BP\\>90 at their index visit\n* have access to the internet\n\nExclusion Criteria:\n\n* not pregnant or within 3 months postpartum\n* severe, uncorrectable vision, hearing, or cognitive impairment that would preclude study consent or participation","FEMALE","44 Years",{"count":336,"type":21},350,[24],"Test the effectiveness of a technology-enabled strategy to optimize blood pressure among reproductive-aged women with hypertension receiving care in Federally Qualified Health Centers.",[27,340,341,342],"Reproductive Behavior","Primary Health Care","Electronic Health Record","2026-06-18",{"date":293,"type":32},{"date":346,"type":32},"2026-06-16",{"date":348,"type":21},"2030-06-30",{"name":38,"class":39},{"id":351,"slug":4,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":22,"phases":358,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":40},"100560022","NCT06571734","XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma","A Non-Randomized, Open-label Phase II Trial Testing the Activity of XL092 (Zanzalintinib) in Patients With Advanced Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma","Inclusion Criteria For Cohort 1 - Leiomyosarcoma:\n\n* Patients must have histologically confirmed leiomyosarcoma that has been clinically determined to be metastatic or unresectable. Pathology must have been reviewed at a National Comprehensive Cancer Network (NCCN) designated cancer center such as Northwestern University's Lurie Cancer Center.\n* Patients must have undergone at least 2 or more lines of antineoplastic treatment, but no more than 2 lines of treatment can be a tyrosine kinase inhibitor (TKI).\n\nInclusion Criteria For Cohort 2 - Bone Sarcoma:\n\n* Patients must have histologically confirmed diagnosis of metastatic or unresectable bone sarcoma. Pathology must have been reviewed at a National Comprehensive Cancer Network (NCCN) designated cancer center such as Northwestern University's Lurie Cancer Center.\n* Patients must have undergone at least 1 line of antineoplastic treatment, but no more than 2 lines of treatment can be a tyrosine kinase inhibitor (TKI).\n\nInclusion Criteria For Cohort 3 - Translocation-associated Soft Tissue Sarcoma:\n\n* Patients must have histologically confirmed diagnosis of metastatic or unresectable translocation-associated soft tissue sarcoma (TAS). Pathology must have been reviewed at a National Comprehensive Cancer Network (NCCN) designated cancer center such as Northwestern University's Lurie Cancer Center.\n* Patients must have undergone greater than 2 lines of antineoplastic treatment, but no more than 2 lines of treatment can be a tyrosine kinase inhibitor (TKI).\n\nInclusion Criteria for All Cohorts\u002FSarcoma Types\n\n* Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.\n* Patients must be aged ≥ 18 years on day of signing any informed consent documents.\n* Patients must exhibit a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale or \\> 70% on the Karnofsky Scale.\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FmcL (without granulocyte colony-stimulating factor support within 21 days of screening sample collection)\n* Hemoglobin (Hgb) ≥ 9 g\u002FdL without transfusion within 21 days of screening laboratory sample collection\n* Platelets (PLT) ≥ 100,000\u002Fmm\\^3 (\\> 100 GI\u002FL) without transfusion within 21 days of screening laboratory sample collection\n* International normalized ratio (INR) ≤ 1.5 ULN and activated partial thromboplastin time (aPTT) ≤ 1.2 x upper limit of normal (ULN)\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal ULN; for patients with Gilbert's disease, total bilirubin ≤ 3 x ULN\n* Alanine aminotransferase (AST) ≤ 3 x institutional ULN\n* Aspartate aminotransferase (ALT) ≤ 3 x institutional ULN\n* Alkaline phosphatase (ALP) ≤ 3 x institutional ULN; for patients with documented bone metastasis, ALP ≤ 5 x ULN\n* Serum creatinine ≤ 1.5 x institutional ULN OR calculated creatinine clearance ≥ 40 mL\u002Fmin ( ≥ 0.67 mL\u002Fsec) using the Cockcroft-Gault equation\n* Creatinine clearance ≥ 40mL\u002Fmin\n* Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg\u002Fmg ( ≤ 113.12 mg\u002Fmmol)\n* Patient of child-bearing potential (POCBP) and any of their partners with sperm-producing reproductive capability must agree to use a highly effective method of contraception throughout the course of the study and for 186 days after the last dose of treatment. Additional contraceptive method, such as a barrier method (e.g., condom) is also required\n* Patients with sperm-producing reproductive capacity (PWSPRC) treated or enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence), with partners of childbearing potential from time of informed consent, for the duration of study participation, and for 96 days following completion of therapy\n* Patients must have ejection fraction \\> 50% by either MUGA scan or echocardiogram.\n* Patients must be capable of understanding and complying with the protocol requirements.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Patients who have received previous treatment with XL092.\n* Patients who have received any type of small-molecule kinase inhibitor (including an investigational kinase inhibitor) within 14 days prior to study day 1 treatment.\n* Patients who have received \\> 2 prior tyrosine kinase inhibitor therapies as anticancer treatments.\n* Patients who have had prior chemotherapy, or radiation therapy within 4 weeks prior to start of study treatment unless they have recovered from their prior therapy (toxicity and\u002For complications) such that they now meet all other eligibility criteria\n* Patients who have received radiation therapy for bone metastasis within 14 days prior to registration\n* Patients who have undergone systemic treatment with radionuclides within 6 weeks (42 days) before first dose of study treatment\n* Patients with clinically relevant complications from prior radiation therapy requiring ongoing therapy, per the opinion of the treating investigator enrolling the patient.\n* Patients with a known prior or concurrent malignancy that is progressing or requires active treatment within 2 years of first dose of study treatment. Note: The following exceptions may be made:\n\n  * For patients with malignancies like basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer; or superficial skin cancers, localized low-grade tumors deemed cured and not treated with systemic therapy, and incidentally diagnosed prostate cancer if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6.\n  * For patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Patients with known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment. Note: Base of skull lesions without definitive evidence of dural or brain parenchymal involvement are allowed. Note: Eligible patients must be neurologically asymptomatic and without corticosteroid treatment at the time of first dose of study treatment.\n* Patients who are on concomitant anticoagulation therapy with oral anticoagulants (e.g., warfarin or direct thrombin and factor Xa inhibitors) and platelet inhibitors (e.g., clopidogrel). Note: Allowed anticoagulants are low-dose aspirin for cardioprotection (per local applicable guidelines) and low molecular weight heparins (LMWH). Therapeutic doses of LMWH are not permitted in patients with brain metastases. Note: Patients must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first study treatment, whichever is longer.\n* Patients who are taking any complementary medications (e.g., herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks (14 days) prior to start of treatment. Note: taking complementary medications to treat symptoms of the cancer is allowed.\n* The patient has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  * Cardiovascular disorders:\n\n    * Congestive heart failure New York Heart Association class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias (e.g., ventricular flutter, ventricular fibrillation, Torsades de pointes)\n    * Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic of \\> 90 mm Hg diastolic despite optimal antihypertensive treatment\n    * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction, or other clinically significant ischemic events within 12 months prior to first dose of study treatment. Note: Patients who did not require prior anticoagulant therapy may be eligible must be discussed and approved by the principal investigator (PI)\n    * Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous or non-cerebrovascular accident (CVA)\u002FTIA arterial thromboembolic events within 6 months before to first dose of study treatment.\n    * Prior history of myocarditis\n  * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\n\n    * Tumors invading the GI tract from external viscera\n    * Active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis\n    * Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess must be confirmed prior to first dose of study treatment\n    * Known gastric or esophageal varices\n    * Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months unless cause of obstruction is definitively managed and subject is asymptomatic\n* Patients with clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 mL) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 84 days prior to registration.\n* Symptomatic cavitating pulmonary lesions or endobronchial disease (asymptomatic or radiated lesions allowed).\n* Lesions invading major blood vessel including but not limited to inferior vena cava, pulmonary artery, or aorta.\n\nNote: Patients with intravascular tumor extension (e.g., tumor thrombus in renal vein or inferior vena cava) may be eligible following PI approval\n\n* Patients who are capable of donating eggs for the purpose of reproduction must not do so throughout the course of the study and for 186 days after the last dose of treatment\n* Patients who are capable of donating sperm for the purpose of reproduction must not do so throughout the course of the study and for 96 days after the last dose of treatment\n* Other clinically significant disorders that would preclude safe study participation, including, but not limited to:\n\n  * Active infection requiring systemic treatment. Note: This criterion applies only at enrollment; if a patient develops an infection while on study treatment, they may continue to receive study treatment. Note: prophylactic antibiotic treatment is allowed\n  * Known infection with acute or chronic hepatitis B or C, known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness\n  * Known positive test for or suspected infection with SARS-CoV-2 within one month prior to enrollment. Note: Demonstration that the patient has fully recovered from the infection is required to be eligible for enrollment\n  * Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if they are due to tumor-associated skin lesions\n  * Malabsorption syndrome\n  * Pharmacologically uncompensated, symptomatic hypothyroidism\n  * Moderate to severe hepatic impairment (Child-Pugh B or C)\n  * Requirement for hemodialysis or peritoneal dialysis\n  * History of solid organ or allogenic stem cell transplant\n* Recent surgery within the following parameters:\n\n  * Major surgery (e.g., GI surgery or removal\u002Fbiopsy of brain metastasis) within 8 weeks prior to study treatment\n  * Minor surgery (e.g., simple excision, tooth extraction) within 5 days prior to first dose of study treatment. Note: if a patient has had a recent surgery outside of the proscribed interval, complete wound healing from said surgery must have occurred prior to first dose of study treatment. Note: Fresh tumor biopsies should be performed at least 5 days prior to registration. Patients with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 480 ms within 14 days per electrocardiogram (ECG) prior to first dose of study treatment Note: Triplicate ECG evaluations will be performed and the average of these 3 consecutive results for QTcF will be used to determine eligibility\n* Patients with any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) grade \\> 1 at baseline from a previous anticancer therapy, with the following exceptions:\n\n  * Alopecia, vitiligo, and the laboratory values\n  * Patients with grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the treating physician\n  * Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with XL092 may be included only after consultation with the principal investigator\n* Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to XL092\n* Patients who are pregnant (positive serum or urine test within 72 hours prior to enrollment) or nursing. Pregnant people are excluded from this study because XL092 is a next-generation tyrosine kinase inhibitor with potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the nursing parent with XL092, breastfeeding should be discontinued if the nursing parent is treated with XL092. Note: If a urine pregnancy test is positive or cannot be confirmed negative, a serum pregnancy test will be required\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, per the opinion of the treating investigator\n* XL092 is administrated orally; patients who are unable to swallow, retain, and\u002For absorb pills are not eligible for this study\n* Patients who are currently participating in or have participated in a study of an investigational agent or have used an investigational device within 4 weeks prior to the first dose of treatment\n* Other conditions which, in the opinion of the Investigator, would compromise the safety of the patient or the patient's ability to complete the study",{"count":357,"type":21},73,[94],"This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Leiomyosarcomas are a type sarcoma that can occur in any location in the body, such as the uterus or in the abdomen. Current standard treatment for leiomyosarcoma only shows a progression-free survival of 4-6 months. XL092, a tyrosine kinase inhibitor, interferes with cell communication and growth and may prevent tumor growth. Giving XL092 may kill more tumor cells in patients with metastatic or unresectable leiomyosarcoma. The trial has now been expanded to treat additional sarcoma types that are sensitive to tyrosine kinase inhibitors (TKIs) such as translocation-associated soft tissue sarcoma (such as synovial sarcoma), and bone sarcoma (including osteosarcoma and Ewing sarcoma).",[361,362,363,364,365,366,367,368,369,370],"Metastatic Leiomyosarcoma","Unresectable Leiomyosarcoma","Bone Sarcoma","Translocation-associated Soft Tissue Sarcoma","Synovial Sarcomas","Osteosarcoma Metastatic","Ewing Sarcoma","Ewing Sarcoma Metastatic","Sarcoma Metastatic","Sarcoma of Bone",{"date":343,"type":32},{"date":373,"type":32},"2024-09-19",{"date":375,"type":21},"2033-07-01",{"name":38,"class":39},{"id":378,"slug":4,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":383,"phases":4,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":387,"startDateStruct":388,"completionDateStruct":390,"leadSponsor":392,"locationsCount":107},"100409795","NCT04616131","Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* Biopsy or cytology proven adenocarcinoma of the pancreas\n* No clinical evidence of metastatic disease on imaging\n* Age 18 or older\n* Receiving chemotherapy for non-metastatic pancreatic cancer\n\nExclusion Criteria:\n\n* Biopsy proven metastatic disease",{"count":20,"type":21},"OBSERVATIONAL","For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.",[386],"Pancreas Cancer",{"date":343,"type":32},{"date":389,"type":32},"2020-10-01",{"date":391,"type":21},"2029-10-01",{"name":38,"class":39},{"id":394,"slug":4,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":398,"eligibilityCriteria":399,"healthyVolunteers":114,"sex":333,"minAge":17,"maxAge":334,"enrollmentInfo":400,"targetDuration":4,"studyType":383,"phases":4,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":40},"100466803","NCT05358483","PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health","The PROMISE Study: PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health","PROMISE","Inclusion Criteria:\n\n* Women ages 18-44 seeking pregnancy at Northwestern Fertility and Reproductive Medicine (FRM) who agree to\n\n  1. Be followed for a period for up to 25 years\n  2. Share information regarding their child's health\n* No prior IVF cycles\n\nExclusion Criteria:\n\n* Women using donor oocytes or gestational carriers\n* Inability or unwillingness to provide informed consent for any aspects of the study",{"count":401,"type":21},1000,"The goal of the PROMISE study is to determine how pre-conception lifestyle factors (e.g., sleep, nutrition, physical activity) affect short- and long-term reproductive outcomes.",[404],"Infertility, Female","2026-06-14",{"date":346,"type":32},{"date":408,"type":32},"2021-09-07",{"date":410,"type":21},"2046-12",{"name":38,"class":39},{"id":413,"slug":4,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":114,"sex":333,"minAge":17,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":383,"phases":4,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":433,"completionDateStruct":434,"leadSponsor":436,"locationsCount":437},"100592558","NCT06994988","ARPA-H Smart Band-Aid to Measure Chronic Pain in Women","Multi-modal Smart Band-Aid for AI-based Quantification of Pain","Inclusion Criteria:\n\nFor chronic pain group:\n\n* Female, 18 years or older.\n* Diagnosis of chronic pain condition (e.g., fibromyalgia, chronic lower back pain) as determined by the Principal Investigator.\n* Ability to provide informed consent.\n\nFor healthy controls:\n\n* Female, 18 years or older.\n* No history of chronic pain.\n* No significant or poorly controlled medical conditions as determined by the Principal Investigator and exclusion criteria.\n* No significant active, poorly controlled psychological conditions as determined by the Principal Investigator and exclusion criteria.\n* Ability to provide informed consent.\n\nExclusion Criteria (both groups):\n\n* Pregnant or breastfeeding women.\n\n  * Substance abuse or psychiatric disorders that interfere with study participation.\n  * Major medical conditions (such as severe cardiovascular, neurological, cancer or autoimmune diseases) or psychological conditions (e.g., active, poorly-controlled depression, anxiety disorder, PTSD, substance use disorder) that interfere with study participation.\n  * Possibility of secondary financial gain from participation\n  * Interventional pain treatment(s) within 6 weeks of baseline (injection, epidural, etc.)\n  * Current opioid usage or usage within 2 weeks of baseline",{"count":419,"type":21},115,"The goal of this clinical trial is to test whether a minimally invasive microneedle patch, called the A-Band (Smart Band-aid), worn on the arm (monitoring key biomarkers in interstitial fluid) and a commercial smartwatch can accurately correlate with self-reported pain in women with chronic pain. A secondary purpose of the study is to identify demographic and clinical variables impacting pain measurement.\n\nThe main questions that this study aims to answer are:\n\n* What is the correlation between AI-adjusted pain scores, based on biomarkers and validated tools, and self-reported pain scores?\n* What influence do demographic and clinical information have in the correlation of these pain scores?\n\nResearchers will compare data from these tools with self-reported pain scores in women with chronic pain and healthy women.\n\nParticipants will:\n\n* Be a part of the study for approximately 8 days\n* Attend 2-3 in-person visits at the applicable clinical center over approximately one week\n* Wear a Smart Band-Aid (A-Band) at least twice per day for a week, with each application lasting up to 90 minutes\n* Complete questionnaires regarding medical history, pain information, mental health, sleep, and demographic data\n* Record daily pain scores\n* Wear a smartwatch for one week which will collect biophysical data (heart rate, skin response, etc.)\n* Collect daily saliva samples\n* Have blood drawn by medical staff at 2 in-person visits",[422],"Chronic Pain",[424,425,422,426,427,428,429],"Smart Band-Aid","A-Band","ARPA-H","AI and Chronic Pain","Objective measure","Biomarker","2026-06-11",{"date":432,"type":32},"2026-06-15",{"date":55,"type":21},{"date":435,"type":21},"2027-04-23",{"name":38,"class":39},2,{"id":439,"slug":4,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":447,"briefSummary":448,"conditions":449,"keywords":451,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":40},"100567321","NCT06666673","Effect of Neural Constraints on Movement in Stroke","ENCMS","Inclusion Criteria:\n\n* History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment\n* Age between 18-80\n* Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 10-50\u002F66, Chedoke McMaster Stroke Assessment Hand section \\\u003C=4)\n* Ability to communicate, understand, and provide informed consent\n* Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate active elbow extension\n* MRI compatible\n* Intact skin on the hemiparetic arm\n* Ability to sit for three hours.\n\nExclusion Criteria:\n\n* Motor or sensory impairment in the non-affected limb (FMA\\\u003C66, filament \\>3.6)\n* Any brainstem and\u002For cerebellar lesion\n* untreated cardiovascular disease\n* History of neurologic disorder other than stroke that affects the arms\n* Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale\n* Current use of a pacemaker\n* History of seizure\n* Chemo denervation: botulinum toxin injection to any portion of the paretic upper extremity within the last 6 months, or phenol\u002Falcohol injections \\\u003C12 months before participation\n* Flexion contractures larger than 30 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) after stretching for 15 minutes\n* Current participation in any experimental rehabilitation or drug studies\n* Individuals with any known contraindications to Tizanidine or currently taking Tizanidine; - concurrent use of medications known to suppress central nervous system activity\n* pregnant women or women who are nursing.\n\nAdditionally, each participant will be asked to provide a list of their current medications and a medical screening questionnaire will be sent to their primary physician. Each participant's list of medications will be reviewed for possible interactions with the study drugs and, at the study physician's advice, will be excluded from the study or asked to withhold medications when applicable. A full list of potential drug interactions can be seen in \"Medication Interactions\", but concisely includes the following: medications with dopaminergic, serotonergic, or noradrenergic actions; central nervous system (CNS) depressants; antihypertensive\u002F antiarrhythmic agents; and hormonal medications\u002Fcontraceptives.","80 Years",{"count":446,"type":21},64,[73],"This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.",[450],"Stroke",[452,453,454,455,456,457,458],"Neurotransmitters","flexion synergy","brain plasticity","tizanidine","stroke","motor control","spasticity",{"date":432,"type":32},{"date":461,"type":32},"2024-08-23",{"date":463,"type":21},"2029-07-31",{"name":38,"class":39},{"id":466,"slug":4,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":472,"briefSummary":473,"conditions":474,"keywords":479,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":437},"100564533","NCT06630416","Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors","A Phase II Trial to Evaluate Pemetrexed Response in Relation to Tumor Alterations of Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma and Other Solid Tumors","Inclusion Criteria:\n\n* Patients must have pathologically or cytologically confirmed metastatic urothelial bladder carcinoma (Arm A) or other metastatic\u002Flocally-advanced solid malignancy (Arm B) and MLL4- protein (KMT2D-gene) or UTX-protein (KDM6A-gene) or MTAP loss of function mutation including but not limited to SNVs that cause truncation, CNVs, and indels confirmed by next generation sequencing or immunohistochemistry techniques.\n* Patients must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), measured preferably by computed tomography (CT) scan.\n* Patients who have received any prior neoadjuvant or systemic chemotherapy are eligible.\n\n  * Notes:\n\n    * Patients must have progressive disease despite two prior lines of therapy in the metastatic setting or locally advanced setting unless the patient was not suitable for an approved second line regimen due to intolerance or another clinical factor;\n    * Treatment cannot have included prior pemetrexed. Any prior intravesical therapy, or immunotherapy is allowed. At least 3 weeks (21 days) wash-out period since prior chemotherapy or radiation therapy or targeted agent is required.\n* Patients must be aged ≥ 18 years.\n* Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Patients must have adequate organ and bone marrow function as defined:\n* Absolute neutrophil count (ANC) ≥ 1,500\u002FmcL (growth factor allowed and can be added at the discretion of the treating oncologist)\n* Hemoglobin (Hgb) ≥ 8.5 g\u002FdL (without the need for transfusion within the previous one week)\n* Platelets (PLT) ≥ 100,000\u002FmL (without the need for platelet transfusion within the previous one week)\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except subjects with Gilbert's syndrome or liver metastases, who must have a baseline total bilirubin ≤ 3.0 mg\u002FdL\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\]) ≤ 3 x institutional ULN or ≤ 5 x ULN if documented liver metastases are present\n* Alanine aminotransferase (ALT) (serum glutamic-pyruvic transaminase \\[SGPT\\]) ≤ 3 x institutional ULN or ≤ 5 x ULN if documented liver metastases are present\n* Creatinine clearance ≥ 45 mL\u002Fmin\u002F1.73 m\\^2 using the standard Cockcroft and Gault formula\n* Patients must have the ability to comply with the administration of supplemental therapies including folic acid, vitamin B12 and steroids as directed by study team and as per standard of care and institutional standards and practice for pemetrexed use.\n* Patients must be able swallow oral medication or not have problems\u002Fdiseases that affect absorption or oral medication.\n* Patients with a known history of human immunodeficiency virus (HIV), infected patients on effective anti-retroviral therapy must have a viral load undetectable for 6 months prior to registration. Please note this lab is not a requirement for eligibility, however, if it was previously done as part of the patient's health care, it should be documented for eligibility.\n* Patients with a known history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Please note this lab is not a requirement for eligibility, however, if the lab has been completed previously as part of the patient's health care, then it should be documented for eligibility.\n* Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with a known HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. Please note this lab is not a requirement for eligibility, however if it was previously done as part of the patient's health care, it should be documented for eligibility.\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Pemetrexed is known to be teratogenic. For this reason, patients of child-bearing potential (POCBP) and their partners with sperm-producing reproductive capacity must agree to use adequate contraception from time of informed consent, for the duration of study participation, and for 180 days following completion of pemetrexed therapy. Should a POCBP become pregnant or suspect they are pregnant while they or their partner are participating in this study, they should inform their treating physician immediately. Patients with sperm-producing reproductive capacity (PWSPRC) treated or enrolled on this protocol must also agree to use adequate contraception with partners of childbearing potential from time of informed consent, for the duration of study participation, and 180 days after completion of administration\n\n  * Note: A POCBP is any patient (regardless of gender, sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) with an egg-producing reproductive tract who meets the following criteria:\n\n    * Has not undergone a hysterectomy or bilateral oophorectomy\n    * Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n* POCBP must have a negative pregnancy test prior to registration on study.\n* The ability to interrupt nonsteroidal anti-inflammatory drugs (NSAIDS) or aspirin at higher dose (\\> 1.3 g per day) 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed.\n* Patients must be able to understand and voluntarily sign a written informed consent and willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures.\n\nExclusion Criteria:\n\n* Patients who received prior pemetrexed containing chemotherapy.\n* Patients who have had chemotherapy or radiotherapy ≤ 21 days (prior to planned treatment start date). For palliative radiation, 5 day wash out is sufficient.\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia, neuropathy and other non-significant adverse events deemed not clinically significant by the treating investigator, adverse events per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).\n* Patients who are receiving any other investigational agents. A 21 day wash out period will be required after discontinuation of an investigational agent prior to first day of study treatment.\n* Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to pemetrexed.\n* Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following:\n\n  * Ongoing or active infection requiring systemic treatment\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.\n\n  * Note: To be eligible for this trial, patients should be class 2B or better\n* Patients with presence of third space fluid which cannot be controlled by drainage\n\n  * Note: For patients who develop or have baseline clinically significant pleural or peritoneal effusions (on the basis of symptoms or clinical examination) before or during initiation of pemetrexed therapy, consideration should be given to draining the effusion prior to dosing. However, if, in the investigator's opinion, the effusion represents progression of disease, the patient should be discontinued from study therapy\n* Has received the final dose of any of the following treatments\u002F procedures with the specified minimum intervals before first dose of study drug:\n\n  * Focal radiation therapy - 7 days\n  * Surgery with general anesthesia - 7 days\n  * Surgery with local anesthesia - 3 days\n  * For palliative radiation - 5 days\n* Patients of child bearing (POCB) potential who are pregnant or nursing.\n\n  * Note: Registration of patients is completed in Northwestern Oncology Trial Information System (NOTIS)",{"count":446,"type":21},[94],"This phase II trial tests how well pemetrexed works in treating patients with urothelial bladder cancer and other solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) with mutations that result in a loss of function in the MLL4-protein\u002FKMT2D-gene or UTX-protein\u002FKDM6A-gene or MTAP enzyme. Loss of function due to a genetic mutation means a gene's activity may be reduced or eliminated. Mutations that result in a loss of function in the MLL4-protein or KMT2D-gene are found in 9.96% of all cancers including bladder carcinoma patients, esophageal squamous cell carcinoma and esophageal adenocarcinoma patients. In addition, mutations that result in a loss of function in the UTX-protein or KDM6A-gene are found in approximately 5% of all tumors, including bladder cancers, endometrial cancer, and esophagogastric cancer amongst many other tumor types. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill tumor cells. Giving pemetrexed may increase response in patients with metastatic urothelial bladder cancer and other solid tumors with the loss of function in the MLL4-protein\u002FKMT2D-gene or UTX-protein\u002FKDM6A-gene or MTAP enzyme.",[475,476,477,478],"Metastatic Bladder Urothelial Carcinoma","Metastatic Malignant Solid Neoplasm","Stage IV Bladder Cancer AJCC v8","MTAP Deletion",[480],"KMT2D (gene)\u002FMLL4 (protein) or KDM6A (gene)\u002FUTX (protein) or MTAP loss of function mutations","2026-06-10",{"date":483,"type":32},"2026-06-12",{"date":485,"type":32},"2024-11-27",{"date":487,"type":21},"2030-05-10",{"name":38,"class":39},{"id":490,"slug":4,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":114,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":22,"phases":498,"briefSummary":499,"conditions":500,"keywords":503,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":40},"100642446","NCT07637630","Trial in HPV Prevention for the U.S. Vietnamese Community","Applying the Multiphase Optimization Strategy to Develop and Test a Culturally-Relevant Digital Health Intervention Targeting HPV Vaccination Among U.S. Vietnamese","HERO","Inclusion Criteria:\n\n* Self-identify as U.S. Vietnamese.\n* Are the parent of a youth ages 9-18 who have not initiated the HPV vaccine series. Only one parent per household will be able to participate.\n* Have lived in the U.S. for 12 months or more.\n\nExclusion Criteria:\n\n* Planning to move out of the U.S. within the next 6 months.\n* Not fluent in either spoken and written Vietnamese or spoken and written English.\n* Inability to provide informed consent.",{"count":497,"type":21},96,[24],"The purpose of the HERO study is to leverage the Multiphase Optimization Strategy (MOST) framework to conduct a pilot trial testing four different intervention components (expert video, self-persuasion, narrative storytelling, and motivational interviewing) targeting HPV vaccination among U.S. Vietnamese.\n\nPRIMARY AIM To assess the feasibility and acceptability of each of the four digital HERO intervention components in a pilot optimization trial using the MOST framework. Using a highly efficient design, the study team will randomize 96 Vietnamese parents of unvaccinated adolescents to receive 0 to 4 HERO components. The study team will establish the feasibility (reach, retention, adherence) and acceptability (usability, satisfaction, usefulness, cultural relevance) of each component (expert video, self-persuasion, narrative storytelling, and motivational interviewing).\n\nSECONDARY AIM To investigate effects of each component on HPV vaccination outcomes and psychosocial mediators. The study team will examine the effects on HPV vaccination (initiation and intention) and psychosocial mediators.",[501,502],"HPV-related Cancers","HPV Vaccination",[504,505,506,507,508,509],"HPV vaccination","digital health intervention","U.S. Vietnamese","MOST framework","behavioral intervention","adolescent vaccination","2026-06-09",{"date":430,"type":32},{"date":513,"type":32},"2026-05-01",{"date":515,"type":21},"2029-06-30",{"name":38,"class":39},{"id":518,"slug":4,"hasResults":11,"nctId":519,"briefTitle":520,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":11,"sex":333,"minAge":17,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":22,"phases":523,"briefSummary":524,"conditions":525,"keywords":527,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":40},"100586238","NCT06912776","Novel Visual Education Tool to Improve Recognition and Reporting of Postpartum Urgent Maternal Warning Signs","Inclusion Criteria:\n\n* Postpartum women\n* Nulliparity\n* Age \\>18 years of age\n* English speaking patients\n\nExclusion Criteria:\n\n* Inability to provide informed written consent\n* Refusal to participate in all study-related procedures\n* Patients not fluent in English\n* Patients with current or history of serious peripartum complications and\u002For events - such as DVT, PE, peripartum cardiomyopathy, etc. (in which the patient may have received more than standard clinical counseling)\n* Patient with comorbidities that potentially require anticoagulation i.e. coagulopathies and may be more prone to DVTs\n* Patients with uncorrected visual or hearing impairment\n* Healthcare providers (in which patients will have significant background knowledge)",{"count":116,"type":21},[24],"This study aims to create a novel visual education tool that builds on the urgent maternal warning signs identified by The Council on Patient Safety in Women's Health Care. Including effective images will improve the understanding of these grave warning signs\u002Fsymptoms, improving anatomical accuracy while remaining simplistic for patients of varying levels of health care literacy. The investigative team will be focusing on urgent warning signs pertinent to the postpartum period.",[526],"Postpartum",[528,526,529],"Pregnancy","nulliparus",{"date":481,"type":32},{"date":532,"type":32},"2025-06-20",{"date":534,"type":21},"2027-07",{"name":38,"class":39},{"id":537,"slug":4,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":22,"phases":545,"briefSummary":546,"conditions":547,"keywords":549,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":40},"100580976","NCT06844305","Personalized Prosthetic Foot Prescription and Rehabilitation for Veterans With Lower Limb Loss","A Personalized, Patient-Centered Prosthetic Foot Prescription and Rehabilitation Strategy to Maximize Mobility and Satisfaction in Veterans With Lower Limb Loss","OPORP","Inclusion Criteria:\n\n* Unilateral transtibial amputation;\n* At least 6 months post-amputation;\n* A comfortable-fitting prosthetic socket that can be used with endoskeletal components;\n* Sufficient walking abilities to safely complete study activities.\n\nExclusion Criteria:\n\n* Major contralateral limb amputation LLL on the contralateral limb;\n* Currently receiving physical therapy related to gait training or prosthesis use.",{"count":544,"type":21},50,[24],"The goal of clinical trial is to assess an integrated, patient-centered strategy combining user preference-based prosthetic foot prescription and subsequent targeted physical therapy to maximize satisfaction and mobility outcomes for Veterans and others with lower limb loss. The main aims it will address are:\n\n* Assess the effect of prosthetic foot selection based on experiential preference as determined using a variable stiffness foot on mobility and satisfaction\n* Assess the effect of a targeted physical therapy intervention following preference-based foot selection on mobility, balance, and satisfaction? Participants will walk with an emulator prosthetic foot to experience three different conditions that emulate different commercial feet to determine their most- and least-preferred foot. Participants' satisfaction, perceived mobility, and functional mobility will be measured and compared between their most- and least-preferred feet using the corresponding commercial feet. Participants will then be randomly assigned to receive either the standard-of-care (control group) or personalized physical therapy intervention for eight weeks using that preferred prosthetic foot. Participants' satisfaction, mobility, and balance will be measured pre- and post-intervention.",[548],"Amputation of Lower Limb",[550,551,552,553,554],"amputation","prosthesis","prescription","physical therapy","personalized",{"date":481,"type":32},{"date":557,"type":21},"2026-12",{"date":559,"type":21},"2029-05",{"name":38,"class":39},{"id":562,"slug":4,"hasResults":11,"nctId":563,"briefTitle":564,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":11,"sex":16,"minAge":566,"maxAge":17,"enrollmentInfo":567,"targetDuration":4,"studyType":22,"phases":568,"briefSummary":569,"conditions":570,"keywords":577,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":587,"locationsCount":40},"100642279","NCT07641244","Experimental Evidence of the Impact of Parental Income on Child Mental Health and Neuroimmune Function","Inclusion Criteria:\n\n* Child of a participant enrolled in the Every Dollar Counts intervention. Youth were between ages 5 and 14 at the start of the intervention (followed up when ages 10 to 18)\n* Biological parent who lives with the child must be part of the original income study\n* For the in-person neuroimaging subsample: family must live within a 2-hour drive of downtown Chicago\n\nExclusion Criteria:\n\n* Youth not between ages 5 and 14 at the start of the intervention\n* Parent not enrolled in the Every Dollar Counts program","10 Years",{"count":20,"type":21},[24],"Growing up in a lower-income family robustly predicts worse mental health in adolescence and early adulthood. How does variability in family income \"get under the skin\" of the developing child and via what mechanisms does it increase risk for mental illness? Moreover, could supplements to family income at critical developmental periods help to prevent later youth mental illness? To address these questions, we leverage an innovative existing double blind randomized controlled trial of 3-years of substantial income supplements to parents.\n\nBy experimentally studying the impacts of these income supplements on families and subsequent youth development, we can examine causal pathways from family income to risk for mental illness via family stress and neuroimmune mechanisms in ways never done before. Moreover, by measuring the longer-term impact of 3 years of income supplements to parents on their child's neuroimmune signaling and risk for mental illness, we can examine the policy implications for child development of unconditional cash transfers to parents and identify how and for whom these supplements help. We will test these basic and translational questions in a sample of 1,200 youth with lower-income parents randomly assigned to receive either a substantial monthly income supplement or a minimal monthly supplement for 3 years, starting when youth were between age 5 - 14 years old. We will follow up with youth and their parent 1 - 2 and 3 - 4 years after the intervention and examine whether income supplements predict better youth mental health during adolescence, as well as whether factors like child age and neighborhood quality modulate intervention effects. Additionally, we explore family stress mechanisms through which the intervention may impact child mental health. Finally, we will measure peripheral inflammation (inflammatory biomarkers and classical monocytes) and use MRI to assess threat, reward, and regulatory neural activity and connectivity among 500 of these youth. Our central hypothesis is that income supplements will decrease family and youth stress and improve parenting, which will improve neuroimmune signaling and decrease risk for psychopathology. Moreover, these effects will remain years after termination of the transfers and be strongest among families who received the intervention earlier in the child's life. This research will provide timely, relevant public health knowledge that will help policy makers understand the longer-term brain, immune, and mental health impacts of cash transfers to parents, while also advancing the science of the sociocontextual and neuroimmune pathways through which variability in family income impacts risk for psychopathology.",[571,572,573,574,575,576],"Psychopathology","Child Mental Health","Anxiety Disorders","Mental Disorders","Inflamation","Poverty",[53,54,578,579,580,576,572,571,581],"Internalizing Disorders","Externalizing Disorders","Inflammation","Stress","2026-06-08",{"date":430,"type":32},{"date":585,"type":32},"2026-04-04",{"date":298,"type":21},{"name":38,"class":39},{"id":589,"slug":4,"hasResults":11,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":114,"sex":69,"minAge":17,"maxAge":594,"enrollmentInfo":595,"targetDuration":4,"studyType":22,"phases":596,"briefSummary":597,"conditions":598,"keywords":601,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":609,"locationsCount":40},"100643473","NCT07632742","Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial","MOSES 2.0 vs Quanta Magneto 150 Holmium Laser for Holmium Laser Enucleation of the prostate-a Randomized Controlled Trial","Inclusion Criteria:\n\n* Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms\n* Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)\n\nExclusion Criteria:\n\n* Patients who lack decisional capacity\n* Patients unable to read\u002Fspeak English\n* Patients who are on a blood thinner (anticoagulation medication)\n* Patients who do not have internet access to complete postoperative surveys","100 Years",{"count":5,"type":21},[24],"The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.",[599,600],"Enlarged Prostate (BPH)","Benign Prostatic Hyperplasia",[602,603],"HoLEP","Holmium laser","2026-06-05",{"date":582,"type":32},{"date":607,"type":21},"2026-06",{"date":210,"type":21},{"name":38,"class":39},""]